Controlling the Ebola virus requires specific treatments. A systematic review and network meta-analysis showed that REGN-EB3 and mAb114 reduced mortality in patients with Ebola compared to ZMapp, remdesivir and standard of care.
The 7840 publications found included 2 randomized controlled trials (RCTs). Compared to standard of care, REGN-EB3 and mAb114 probably resulted in decreased mortality (relative risks of 0.40 and 0.42, respectively; both with moderate certainty). It is uncertain whether ZMapp (RR 0.60; very low confidence) and remdesivir (RR 0.64; very low confidence) reduce mortality compared to standard care.
With a high degree of certainty, REGN-EB3 reduced mortality compared to ZMapp (RR 0.67) and remdesivir (RR 0.63). Also mAb114 significantly reduced mortality compared to ZMapp (RR 0.71) and remdesivir (RR 0.66).
Compared to standard of care, REGN-EB3, mAb114, ZMapp and remdesivir are likely to have little or no effect on the time to viral clearance. The mean decrease ranged from 0.25 to 1.14 days (low confidence). ZMapp could shorten the hospital stay compared to standard care (average decrease of 2.02 days; low certainty).
According to the authors, these findings indicate that REGN-EB3 and mAb114 are the preferred treatments for patients with Ebola in future outbreaks.
Bron:
Gao Y, Zhao Y, Guyatt G, et al. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe. 2022 Jul 5. Online ahead of print.
–
